```
=> file caplus
FILE 'CAPLUS' ENTERED AT 13:56:51 ON 29 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Mar 2005  VOL 142 ISS 14
FILE LAST UPDATED: 28 Mar 2005  (20050328/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d que
L1              STR
```




```
G1 O,S


Structure attributes must be viewed using STN Express query preparation.
L3           33 SEA FILE=REGISTRY SSS FUL L1
L5           10 SEA L3


=> => d l4 1-17 fbib abs hitstr

L4   ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:1019782  CAPLUS
DN   142:6433
TI   Preparation of aryl amides, arylpropenamides, and arylpentadienamides as
     promoters of apolipoprotein AI expression for the treatment of
     dyslipidemia and arteriosclerotic diseases
IN   Yamamori, Teruo; Nagata, Kiyoshi; Ishizuka, Natsuki; Sakai, Katsunori
PA   Japan
SO   U.S. Pat. Appl. Publ., 43 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
```

PI US 2004235888 A1 20041125 US 2004-489333 20040421
WO 2001-JP7980 W 20010914

OS MARPAT 142:6433

AB Amides Ar1(R)NC(:Z)(CY2:CY1)nA and Ar1(R)NC(:Z)(CHY2CHY1)nA [A = Ar2, optionally fused with a monocyclic carbocycle or heterocycle; Ar1, Ar2 = mono- or bicyclic aromatic carbocycle or heterocycle; R = H, (un)substituted alkyl; Y1, Y2 = H, halogen, HO2C, NC, (un)substituted alkyl, alkoxycarbonyl, Ph, aromatic heterocyclyl; Z = O, S; n = 0-2] such as N-2-pyridinyl trans-β-(2-furanyl)acrylamide (I) and N-Ph trans-cinnamide (II) are prepared as promoters of apolipoprotein AI expression for the treatment of dyslipidemia and arteriosclerotic diseases. I is prepared in 57% yield by condensation of 2-pyridineamine and trans-2-furylacrylic acid with bromotrichloromethane and triphenylphosphine in THF. The minimal EDs for enhancement of human apolipoprotein AI expression by some compds. of the invention are given. E.g., II enhances human apolipoprotein AI expression with a minimal ED of 0.13 μg/mL.

IT **62289-86-5P 340258-78-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl amides, arylpropenamides, and arylpentadienamides as promoters of apolipoprotein AI expression for the treatment of dyslipidemia and arteriosclerotic diseases)

RN 62289-86-5 CAPLUS
CN 1H-Indole-2-carboxamide, 1-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 340258-78-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-2-pyridinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:934332 CAPLUS
DN 141:379914
TI A preparation of indolecarboxamide and thieno[2,3-b]pyrrolecarboxamide derivatives, useful as antidiabetic agents
IN Bussolotti, Donald L.; Gammill, Ronald B.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

PI US 2004220229 A1 20041104 US 2004-837468 20040430
US 2003-466667P P 20030430
WO 2004096768 A1 20041111 WO 2004-IB1400 20040423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003-466667P P 20030430
OS MARPAT 141:379914
GI



I



II

AB The invention relates to a preparation of indolecarboxamide and thieno[2,3-b]pyrrolecarboxamide derivs. of formula I [wherein: R1 is (un)substituted indol-2-yl or 2-chlorothieno[2,3-b]pyrrol-5-yl; R2 is alkyl substituted with 1-3 fluorine atoms; R3 is H, NO2, NH2, or NH-alkyl, etc.; X is N, CH, or C-O-alkyl; Z is O or S], useful in treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic retinopathy, hypertension, hyperlipidemia, and atherosclerosis, etc. For instance, indolecarboxamide derivative II was prepared via amidation of 5-chloro-1H-indole-2-carboxylic acid by 2-amino-4-(ethylsulfonyl)-6-nitrophenol with a yield of 62% (example 1).

IT **783370-03-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolecarboxamide and thieno[2,3-b]pyrrolecarboxamide derivs., useful as antidiabetic agents)

RN 783370-03-6 CAPLUS
CN 1H-Indole-2-carboxamide, N-[6-amino-4-(ethylsulfonyl)-2-pyridinyl]-5-chloro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:902369 CAPLUS
DN 141:379911
TI N-(Pyridin-2-yl)-substituted bicyclic heterocyclic carboxamide derivatives as antidiabetic agents, and their preparation, pharmaceutical compositions, and methods of use as inhibitors of glycogen phosphorylase
IN Bussolotti, Donald L.; Gammill, Ronald B.
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004092158	A1	20041028	WO 2004-IB1198	20040405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2003-463691P	P 20030417
US 2004229916	A1	20041118	US 2004-825279	20040415
			US 2003-463691P	P 20030417

OS MARPAT 141:379911
GI



I

Q1 = 

Q2 = 



II

AB The invention provides title compds. I, the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compds., stereoisomers, and prodrugs [wherein: R1 = Q1 or Q2; R = 1-3 of H, NH2, cyano, NO2, halo, alkyl, or alkoxy; R2 = alkoxy; Ra, Rb = Me or OH, provided that both are not OH simultaneously; X = CH2OH, CO2Rc; Rc = H, alkyl, or CON(heterocycloalkyl); Z = O or S]. Also provided are pharmaceutical compns. and uses of I, particularly for the treatment of atherosclerosis, diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, hyperglycemia, hypertension, tissue ischemia, or myocardial ischemia. The compds. are inhibitors of glycogen phosphorylase (no data). Prepns. of approx. 7 compds. and various intermediates are given. For instance, coupling of 3-ethoxy-2-nitropyridine with Et 2-chloropropionate using NaH in DMF, with di-Me sulfate quenching, and reduction of the nitro group to amino with ammonium formate, gave 2-(6-amino-5-ethoxypyridin-3-yl)-2-methylpropionic acid Et ester. Amidation of this intermediate with the acid chloride of 5-chloro-1H-indole-2-carboxylic acid gave invention compound II.

IT **781614-93-5P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid ethyl ester
781615-11-0P, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid sodium salt
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of N-pyridinyl bicyclic heterocyclic carboxamides as antidiabetics and inhibitors of glycogen phosphorylase)

RN 781614-93-5 CAPLUS

CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 781615-11-0 CAPLUS
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT **781614-91-3P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-methylpropionic acid ethyl ester **781614-95-7P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid **781614-96-8P**, 5-Chloro-1H-indole-2-carboxylic acid N-[5-(1,2-dihydroxy-1-methylethyl)-3-ethoxypyridin-2-yl]amide **781614-98-0P**, 5-Chloro-1H-indole-2-carboxylic acid N-[3-ethoxy-5-[1-hydroxy-1-methyl-2-(morpholin-4-yl)-2-oxoethyl]pyridin-2-yl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-pyridinyl bicyclic heterocyclic carboxamides as antidiabetics and inhibitors of glycogen phosphorylase)

RN 781614-91-3 CAPLUS
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α,α-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 781614-95-7 CAPLUS
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl- (9CI) (CA INDEX NAME)



RN 781614-96-8 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[5-(1,2-dihydroxy-1-methylethyl)-3-ethoxy-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 781614-98-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[3-ethoxy-5-[1-hydroxy-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:546476 CAPLUS
DN 141:106368
TI Preparation and use of substituted 2,5-diamidoindoles for the treatment of urological diseases
IN Ergueden, Jens; Krahn, Thomas; Schroeder, Christian; Stasch, Johannes Peter; Weigand, Stefan; Wild, Hanno; Brands, Michael; Siegel, Stephan; Heimbach, Dirk; Keldenich, Joerg; Tajimi, Masaomi; Matsumoto, Hiroko
PA Bayer Healthcare A.-G., Germany
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056768	A2	20040708	WO 2003-EP13819	20031206
	WO 2004056768	A3	20040805		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 2002-28718 A 20021220

OS MARPAT 141:106368

GI



I



II

AB The title compds. [I; R1 = alkyl, alkenyl, (CH2)nG (wherein G = cycloalkyl, 5-6 membered heterocyclyl having 1-2 O atoms; n = 0-4); R2 = alkyl, (CH2)mcycloalkyl, (CH2)mheterocyclyl, (CH2)maryl, (CH2)mheteroaryl (m = 0-4); R3 = (CH2)ocycloalkyl, (CH2)oheterocyclyl, (CH2)oaryl, (CH2)oheteroaryl (o = 0-4); R4 = H, alkyl, (CH2)pcycloalkyl, (CH2)pheterocyclyl, (CH2)paryl, (CH2)pheteroaryl (p = 0-4)], useful for the preparation of medicaments for treating urol. disorders in humans and/or animals, were prepared Thus, amidation of the amine II [R = H] (preparation given) with 3,3-dimethylbutyryl chloride in the presence of Et3N in CH2Cl2 afforded 45% II [R = Me3CCH2CO]. Biol. data (IC50's against ECE) for representative compds. I were given. Medicaments for treating urol. disorders comprising the compound I are claimed.

IT **509149-88-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of urol. diseases)

RN 509149-88-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-(5-amino-2-pyridinyl)-5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT **509150-45-2P 509150-46-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and use of substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of urol. diseases)

RN 509150-45-2 CAPLUS
CN Carbamic acid, [6-[[[5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-1H-indol-2-yl]carbonyl]amino]-3-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 509150-46-3 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-N-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:515503 CAPLUS
DN 141:71452
TI Preparation of pyridine derivatives as JNK inhibitors
IN Kallin, Elisabeth; Plobeck, Niklas; Swahn, Britt-Marie
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004052880	A1	20040624	WO 2003-SE1911	20031208

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

SE 2002-3654 A 20021209

OS MARPAT 141:71452
GI



I

AB The title compds. [I; R1 = aryl or heteroaryl, each of which is optionally substituted with one or more of R3, OR3, OCOR3, COOR3, COR3, CONR3R4, NHCOR3, NR3R4, NHSO2R3, SO2R3, SO2NR3R4, SR3, CN, halo, NO2; R2 = R5, R6, COR5, COR6, CONHR5, CONHR6, CON(R6)2, COOR5, COOR6, SO2R5, SO2R6; R3, R4 = H, alkyl, cycloalkyl, etc.; R5 = (un)substituted (hetero)aryl; R6 = H, alkyl, cycloalkyl, etc.], were prepared and formulated. E.g., a 4-step synthesis of N,N'-bis[4-(trifluoromethyl)phenyl]-4,4'-bipyridine-2,2'-diamine, starting from 2-chloropyridine, was given. Typical Ki values for the compds. I are in the range of about 0.001 to about 10,000 nM in assay for inhibition of JNK3.

IT **712268-63-8P 712268-95-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4,4-bipyridine-2,2'-diamine derivs. as JNK inhibitors)

RN 712268-63-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[2'-(phenylamino)[4,4'-bipyridin]-2-yl]- (9CI) (CA INDEX NAME)



RN 712268-95-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[2'-(phenylamino)[4,4'-bipyridin]-2-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:875249 CAPLUS
DN 139:364824
TI Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors for treatment of diabetes
IN Onda, Kenichi; Suzuki, Takayuki; Shiraki, Ryota; Yonetoku, Yasuhiro; Ogiyama, Takashi; Maruyama, Tatsuya; Momose, Kazuhiro
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003091213	A1	20031106	WO 2003-JP5198	20030423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2002-123926	A 20020425

OS MARPAT 139:364824
GI



I



II

AB The title compds. I [wherein ring A = aryl or aromatic heterocyclyl; ring B = benzene or thiophene; R1-R9 = independently H, halo, OH, alkoxy, aryl, aryloxy, alkyl-CO-, alkyl-CH(OH)-, aryl-CO-, aryl-CH(OH)-, HO-alkylene, NH2, CN, CO2H, oxo, CO2-alkyl, aryl-alkylene(oxy), aryl-CONH-, (un)substituted alkyl, -O-alkylene-CO2H, or -O-alkylene-CONH2; R10 = H or alkyl; R11 = H, alkyl, or aryl-alkylene-; R12-R15 = independently H, OH, halo, alkoxy, HO-alkylene-, aryloxy, aromatic heterocyclyl, aryl-alkylene-, HO2C-alkylene-, -alkylene-CO2-alkyl, acyl, alkyl-CO2, alkyl-CH(OH)-, aryl-CH(OH)-, (un)substituted alkyl, -alkylene-CONH2, or aryl; etc.] and salts thereof are prepared as glycogen phosphorylase inhibitors. I are useful for the treatment of insulin-dependent diabetes (type 1 diabetes), insulin-independent diabetes (type 2 diabetes), insulin resistant disease, and obesity (no data). For example, the compound II was prepared in a multi-step synthesis. II showed IC50 of 0.25 μM against human glycogen phosphorylase.

IT **620596-19-2P 620596-21-6P 620596-22-7P 620596-57-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indolecarboxamide derivs. as glycogen phosphorylase inhibitors for treatment of diabetes)

RN 620596-19-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[5-(1,2-dihydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620596-21-6 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[3-chloro-5-(1,2-dihydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620596-22-7 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[5-(1,2-dihydroxyethyl)-6-methyl-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620596-57-8 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[5-(1,2-dihydroxyethyl)-1-oxido-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT **620596-72-7P 620596-75-0P 620596-90-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolecarboxamide derivs. as glycogen phosphorylase inhibitors for treatment of diabetes)

RN 620596-72-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-(5-bromo-2-pyridinyl)-5-chloro- (9CI) (CA INDEX NAME)



RN 620596-75-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-(5-ethenyl-6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 620596-90-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-(5-ethenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:551374 CAPLUS
DN 139:117331
TI Preparation of polyamide analogs possessing antibacterial, antifungal, and/or antitumor activity
IN Dyatkina, Natalia B.; Shi, Dong-fang; Roberts, Christopher Don; Velligan, Mark Douglas; Liehr, Sebastian Johannes Reinhard; Botyanszki, Janos; Zhang, Wentao; Khorlin, Alexander; Nelson, Peter Harold; Muchowski, Joseph Martin
PA Genelabs Technologies, Inc., USA; et al.
SO PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057212	A1	20030717	WO 2002-US41087	20021224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-343796P	P 20011226
			US 2001-343829P	P 20011226
US 2003212113	A1	20031113	US 2002-328710	20021224
			US 2001-343796P	P 20011226
			US 2001-343829P	P 20011226
BR 2002007583	A	20040427	BR 2002-7583	20021224
			US 2001-343796P	P 20011226
			US 2001-343829P	P 20011226

			WO 2002-US41087	W	20021224
NO 2003003773	A	20031023	NO 2003-3773		20030825
			US 2001-343796P	P	20011226
			US 2001-343829P	P	20011226
			WO 2002-US41087	W	20021224

OS MARPAT 139:117331
GI



I

AB Compds. of formula R1Z1COX1NHCOX2CONHX3COZ2R2 [wherein Z1 and Z2 = independently NR3, O; R3 = H, alkyl; R1 and R2 = independently substituted alkyl or aryl, (un)substituted heteroaryl; X2 = (un)substituted aryl or heteroaryl, alkenyl, alkynyl, cycloalkyl, heterocyclic; X1 and X3 = independently (un)substituted aryl or heteroaryl, CHR4; R4 = (un)natural amino acid side chain; or their pharmaceutically acceptable salts] were prepared as topoisomerase inhibitors (no data) for use as antibacterial, antifungal, and/or antitumor agents. For example, 1H-indole-2,5-dicarboxylic acid dipentafluorophenyl ester was reacted with at least two equivalent of 4-amino-1-methyl-1H-pyrrole-2-carboxylic acid [2-(carbamimidoyl)ethyl]amide in DMF to give I. Compds. of the invention exhibited antibacterial and antifungal activity with some having minimal inhibitory concns. of <45.5 μM. DNA binding assays showed that invention compds. bind to DNA very tightly, with apparent Kd,app values below 100 nM for most compds. tested.

IT **386252-14-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of polyamides as antibacterial, antifungal, and/or antitumor agents)

RN 386252-14-8 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)





RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:335082 CAPLUS
DN 138:353834
TI Preparation of indolecarboxamides as protein kinase and phosphatase inhibitors
IN Hangauer, David G., Jr.; El-Araby, Moustafa E.; Milkiewicz, Karen L.; Nicotera, Thomas; Henderson, Donald
PA The Research Foundation of State University of New York, USA; Roswell Park Cancer Institute
SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2003035621	A1	20030501	WO 2002-US33660		20021019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2001-336191P	P	20011022
			US 2002-410726P	P	20020913
US 2003166615	A1	20030904	US 2002-277217		20021019
			US 2001-336191P	P	20011022
US 2004019015	A1	20040129	US 2002-277220		20021019
			US 2001-336191P	P	20011022
			US 2002-410726P	P	20020913
EP 1444204	A1	20040811	EP 2002-773833		20021019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
			US 2001-336191P	P	20011022
			US 2002-410726P	P	20020913
			WO 2002-US33660	W	20021019

OS MARPAT 138:353834
GI



I

AB The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors I [X = halogen; R1-R6 = (un)substituted acyl, CONH2, CO2H, C(O)SH, OH, NH2, NHCONH2, SH, P(O)(OH)2, B(OH)2, halogen, aryl, heteroaryl, biaryl, heterocyclic, alkyl; NR5R6 = heterocyclic] were prepared Thus, N-(3-fluorobenzyl)-5-fluoro-1H-indole-2-carboxamide was prepared by amide coupling and gave 26% inhibition of epidermal growth factor receptor tyrosine kinase at 10 μM. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, diabetes, or obesity. In addition, the present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

IT **518060-39-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolecarboxamides as protein kinase and phosphatase inhibitors)

RN 518060-39-4 CAPLUS

CN 1H-Indole-2-carboxamide, 5-fluoro-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:282390 CAPLUS

DN 138:304157

TI Preparation of substituted 2,5-diamidoindoles as endothelin-converting enzyme (ECE) inhibitors for the treatment of cardiovascular diseases

IN Ergueden, Jens-kerim; Krahn, Thomas; Schroeder, Christian; Stasch, Johannes-peter; Weigand, Stefan; Wild, Hanno; Brands, Michael; Siegel, Stephan; Heimbach, Dirk; Keldenich, Joerg

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003028719	A1	20030410	WO 2002-EP10349	20020916
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10147672	A 20010927
	DE 10147672	A1	20030410	DE 2001-10147672	20010927
	EP 1432415	A1	20040630	EP 2002-767488	20020916
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				DE 2001-10147672	A 20010927
				WO 2002-EP10349	W 20020916
	US 2005038101	A1	20050217	US 2004-490821	20040916
				DE 2001-10147672	A 20010927
				WO 2002-EP10349	W 20020916

OS MARPAT 138:304157

GI



I



II

AB Title compds. I [R1 = alkyl, alkenyl, etc.; R2 = (cyclo)alkyl, aryl, etc.; R3 = cycloalkyl; heterocyclyl, aryl, etc.; R4 = H, alkyl, cycloalkyl, heterocyclyl, etc.] are prepared For instance, 5-nitro-1-(2-fluorobenzyl)-1H-indol-2-carboxylic acid Et ester (preparation given) is saponified (DMSO, water, KOH), coupled to aniline (CH2Cl2, SOCl2), reduced to the aniline derivative (EtOH, SnCl2) and acylated to give II. II has IC50 = 1 μM for the endothelin-converting enzyme (ECE). I are useful for the treatment of

cardiovascular diseases.

IT **509149-88-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2,5-diamidoindoles as endothelin-converting enzyme (ECE) inhibitors for treatment of cardiovascular diseases)

RN 509149-88-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-(5-amino-2-pyridinyl)-5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT **509150-45-2P 509150-46-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted 2,5-diamidoindoles as endothelin-converting enzyme (ECE) inhibitors for treatment of cardiovascular diseases)

RN 509150-45-2 CAPLUS

CN Carbamic acid, [6-[[[5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-1H-indol-2-yl]carbonyl]amino]-3-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 509150-46-3 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-N-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:159952 CAPLUS
DN 138:368703
TI New N-pyridinyl(methyl)-indole-2- and 3-(Alkyl)carboxamides and Derivatives Acting as Systemic and Topical Inflammation Inhibitors
AU Breteche, Anne; Duflos, Muriel; Dassonville, Alexandra; Nourrisson, Marie-Renee; Brelet, Jacques; Le Baut, Guillaume; Grimaud, Nicole; Petit, Jean-Yves
CS Laboratoires de Chimie Organique et de Chimie Therapeutique, UPRES EA 1155, Faculte de Pharmacie, Nantes, 44035, Fr.
SO Journal of Enzyme Inhibition and Medicinal Chemistry (2002), 17(6), 415-424
CODEN: JEIMAZ; ISSN: 1475-6366
PB Taylor & Francis Ltd.
DT Journal
LA English
OS CASREACT 138:368703
GI



I



II



III

AB A series of novel N-substituted-(indol-2-yl) carboxamides, e.g. I, and (indol-3-alkyl)carboxamides, e.g. II, were synthesized and evaluated as inhibitors of the inflammation process. Pharmacomodulation at the level of the amidic nitrogen by incorporation of the previously described pharmacophoric moieties 6-aminolutidine, β-picolylamine, 4-aminopyridine and piperazine was investigated; only two compds. I and II exhibited significant (~40%) inhibitory effect in the carrageenan-induced rat paw edema after oral administration of a dose of 0.1mMkg-1. Replacement of the indole core by indazole failed to increase activity. Incorporation of an alkyl chain spacer led to more efficient compds., e.g. III (X=H or F), especially in the indolepropanamide sub-series. Determination of the efficiency of the most active compds. on topical inflammation, by measuring reductio of ear thickness in the acute tetradecanyol phorbol acetate (TPA)-induced mouse ear swelling assay, confirmed the high potency of propanamides III (X=H or F) after oral administration: ID50=0.041±0.013 and 0.042±0.016mMkg-1 resp. The less toxic propanamide III (X=F) exerted a high level of inhibitory activity after topical application of 2 x 100μg/ear: 78±2%.

IT **142877-66-5P 521276-45-9P 521276-46-0P 521276-47-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of N-pyridinyl(methyl)-indole-2- and 3-(alkyl)carboxamides and derivs. acting as systemic and topical inflammation inhibitors)

RN 142877-66-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-(4,6-dimethyl-2-pyridinyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 521276-45-9 CAPLUS
CN 1H-Indole-2-carboxamide, N-(4,6-dimethyl-2-pyridinyl)-1-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 521276-46-0 CAPLUS
CN 1H-Indole-2-carboxamide, 3-bromo-N-(4,6-dimethyl-2-pyridinyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 521276-47-1 CAPLUS
CN 1H-Indole-2-carboxamide, 3-bromo-N-(4,6-dimethyl-2-pyridinyl)-1-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:737351 CAPLUS
DN 138:265138
TI Synthesis and antioxidant properties of novel N-substituted indole-2-carboxamide and indole-3-acetamide derivatives
AU Olgen, Sureyya; Coban, Tulay
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ankara, Ankara, 06100, Turk.
SO Archiv der Pharmazie (Weinheim, Germany) (2002), 335(7), 331-338
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 138:265138
AB A series of N-substituted indole-2-carboxamide and indole-3-acetamide derivs. have been prepared and their in vitro effects on rat liver lipid peroxidn. levels and superoxide anion formation were determined The results clearly demonstrate that indole derivs. 4, 5, 10, 15, 17 are very efficient antioxidants compared to α-tocopherol.
IT **503617-64-9P 503617-70-7P 503617-71-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, antioxidative effect and structure-activity relationship of novel N-substituted indole-2-carboxamide and indole-3-acetamide derivs.)
RN 503617-64-9 CAPLUS
CN 1H-Indole-2-carboxamide, N-(6-methyl-2-pyridinyl)-1-phenyl- (9CI) (CA INDEX NAME)



RN 503617-70-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-(6-methyl-2-pyridinyl)-1-(phenylmethyl)- (9CI)

(CA INDEX NAME)



RN 503617-71-8 CAPLUS
CN 1H-Indole-2-carboxamide, 1-(4-methylbenzoyl)-N-(6-methyl-2-pyridinyl)-(9CI) (CA INDEX NAME)



IT **503617-68-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, antioxidative effect and structure-activity relationship of novel N-substituted indole-2-carboxamide and indole-3-acetamide derivs.)
RN 503617-68-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10469 CAPLUS
DN 136:85750
TI Preparation of novel compounds possessing antibacterial, antifungal or antitumor activity
IN Zhang, Wentao; Liehr, Sebastian Johannes R.; Velligan, Mark Douglas; Dyatkina, Natalia B.; Botyanszki, Janos; Shi, Dong-Fang; Roberts, Christopher Don; Khorlin, Alexander; Nelson, Peter Harold; Muchowski, Joseph Martin
PA Genelabs Technologies, Inc., USA
SO PCT Int. Appl., 141 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000650	A2	20020103	WO 2001-US20334	20010626
WO 2002000650	A3	20021024		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-214478P	P 20000627
CA 2414512	AA	20020103	CA 2001-2414512	20010626
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
US 2002037856	A1	20020328	US 2001-892327	20010626
US 6849713	B2	20050201		
			US 2000-214478P	P 20000627
EP 1294713	A2	20030326	EP 2001-948740	20010626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
BR 2001012030	A	20030429	BR 2001-12030	20010626
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
JP 2004501915	T2	20040122	JP 2002-505774	20010626
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
NZ 522839	A	20041126	NZ 2001-522839	20010626
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
US 2003119749	A1	20030626	US 2002-277666	20021023
			US 2000-214478P	P 20000627
			US 2001-892327	A3 20010626
NO 2002005720	A	20030226	NO 2002-5720	20021128
			US 2000-214478P	P 20000627
			WO 2001-US20334	W 20010626
ZA 2002009774	A	20040302	ZA 2002-9774	20021202
			US 2000-214478P	P 20000627

OS MARPAT 136:85750
GI



I

AB Compds. of formula R1Z1COX1NHCOX2CONHX3COZ2R2 (Z1 and Z2 = independently NR3, O; R3 = H, alkyl; R1 and R2 = independently substituted alkyl or aryl, (un)substituted heteroaryl; X2 = (un)substituted aryl or heteroaryl, alkenyl, alkynyl, cycloalkyl, heterocyclic; X1 and X3 = independently (un)substituted aryl or heteroaryl, CHR4; R4 = (un)natural amino acid side chain) or their pharmaceutically acceptable salts were prepared and possess one or more of the following activities: antibacterial, antifungal and antitumor activity. For example, 1H-Indole-2,5-dicarboxylic acid dipentafluorophenyl ester was reacted with at least two equivalent of 4-amino-1-methyl-1H-pyrrole-2-carboxylic acid (2-carbamimidoyl-ethyl)-amide in DMF to give compound I. Compds. of this invention exhibited antibacterial and antifungal activity with some having minimal inhibitory concns. of <45.5 μM. Studies of their DNA binding properties demonstrated that they bind to DNA very tightly, with apparent Kd,app values below 100 nM for most compds. tested.

IT **386252-14-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel compds. possessing antibacterial, antifungal or antitumor activity)

RN 386252-14-8 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:366093 CAPLUS
DN 134:361366
TI Amides as apolipoprotein A-I expression stimulators
IN Yamamori, Teruo; Nagata, Kiyoshi; Ishizuka, Natsuki; Sakai, Katsunori
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 40 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001139550	A2	20010522	JP 1999-326416	19991117
				JP 1999-326416	19991117

OS MARPAT 134:361366
GI



I

AB The stimulators, useful for treatment of arteriosclerosis and blood lipid disorder, comprise I [A = (un)substituted mono or dicyclic aromatic hydrocarbyl, heterocyclyl, etc.; Ar1 = (un)substituted mono or dicyclic aromatic hydrocarbyl, heterocyclyl; R = H, (un)substituted lower alkyl; Z = O, S; Y1, Y2 = H, halo, (un)substituted lower alkyl, CO2H, (un)substituted lower alkoxycarbonyl, cyano, etc.; n = 0-2; dotted line represents optional double bond], their prodrug, pharmaceutically acceptable salts, or hydrates. P-toluidine was reacted with p-chlorobenzoyl chloride in the presence of pyridine in CHCl3 at room temperature for 5 h to give 81.6% 4-chloro-N-(4-tolyl)benzamide showing good stimulating activity for promoting human apolipoprotein A-I production gene.

IT **340258-78-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amides as apolipoprotein A-I expression stimulators)

RN 340258-78-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-2-pyridinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:57804 CAPLUS
DN 124:164314
TI Non-carboxylic antiinflammatory compounds. III. N-(4,6-Dimethylpyridin-2-yl)arylcarboxamides and arylthiocarboxamides acting as brain edema inhibitors
AU Robert J. M. H.; Robert-Piessard, S.; Courant, J.; Le Baut, G.; Robert, B.; Lang, F.; Petit, J. Y.; Grimaud, N.; Welin, L.
CS Lab. chimie organique chimie therapeutique, Faculte pharmacie, Nantes, 44035, Fr.
SO European Journal of Medicinal Chemistry (1995), 30(12), 915-24
CODEN: EJMCA5; ISSN: 0223-5234
PB Elsevier
DT Journal
LA English
GI



I



II

AB Pharmacomodulation of the non-carboxylic NSAID N-(4,6-dimethylpyridin-2-yl)benzamide led to the synthesis of structurally related furan, thiophene and pyrrole carboxamides. Benzenethiocarboxamides and heteroarylthiocarboxamides were also prepared by oxygen/sulfur exchange; this reaction was more efficiently carried out by P4S10 than by Lawesson's reagent. The 20 synthesized compds. were evaluated against peripheral edema by a foot-pad carrageenin-induced edema test. Two amides, (I) and (II), were selected for evaluation of their inhibitory activity in PLA2-induced brain edema and were more potent than dexamethasone after IP administration.

IT **142877-66-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory structure activity of arylthiocarboxamides and benzenethiocarboxamides)

RN 142877-66-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-(4,6-dimethyl-2-pyridinyl)-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:501515 CAPLUS

DN 117:101515

TI N-(4,6-dimethylpyridin-2-yl)(1-methylindol-2-yl)carboxamide

AU Rodier, N.; Cense, J. M.; Robert, J. M.; Le Baut, G.

CS Lab. Chim. Miner., Fac. Sci. Pharm. Biol., Chatenay-Malabry, 92296, Fr.

SO Acta Crystallographica, Section C: Crystal Structure Communications (1992), C48(6), 1148-50
CODEN: ACSCEE; ISSN: 0108-2701

DT Journal

LA French

AB The title compound is orthorhombic, space group P212121, with a 6.3847(8), b 10.234(1), and c 22.251(3) Å; Z = 4, dc = 1.276, T = 294(1) K, R = 0.048 for 1019 reflections. Atomic coordinates are given. The whole mol. is approx. planar. The least-squares planes of the pyridyl ring and the indolyl group make an angle of 2(2)°. The intramol.

C(3)-H(3)···O(20) H bond [2.859(5) Å, 118(3)°)] forms a pseudo-cycle and contributes to the planarity of the mol. There is a delocalized orbital along the amide group. The title compound belongs to a family whose numerous members proved to have anti-inflammatory properties. Its crystal structure was solved to compare its mol. geometry with the geometries of active mols.

IT **142877-66-5**
RL: PRP (Properties)
(crystal structure of)

RN 142877-66-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-(4,6-dimethyl-2-pyridinyl)-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:231432 CAPLUS

DN 110:231432

TI Preparation of N-substituted indolecarboxamides and indolemethylamines as nervous system agents

IN Uhlendorf, Joachim; Borbe, Harald; Ruecker, Werner

PA Nattermann, A., und Cie. G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 7 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3705934	A1	19880908	DE 1987-3705934	19870225
			DE 1987-3705934	19870225

OS CASREACT 110:231432; MARPAT 110:231432

GI



I

AB The title compds. [I; R1 = H, halo, Me, MeO; R2,R3 = H, Me, Et; R4 = pyridyl, imidazolyl, 5-methylisoxazolyl, pyrimidinyl, pyridazinyl, (un) substituted Ph, thiazolyl; Z = CO, CH2] were prepared as nervous system agents (no data). 3-Methoxy-1-methylindole-2-carbonyl chloride was stirred 12 h with 2-aminopyridine in CH2Cl2 containing Et3N to give N-(2-pyridyl)-3-methoxy-1-methylindolecarboxamide.

IT **120271-92-3P 120271-95-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as nervous system agent)
RN 120271-92-3 CAPLUS
CN 1H-Indole-2-carboxamide, 3-methoxy-1-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 120271-95-6 CAPLUS
CN 1H-Indole-2-carboxamide, 3-hydroxy-1-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1977:139898 CAPLUS
DN 86:139898
TI Syntheses of thieno[2,3-c]-, pyrrolo[2,3-c]-, and indolo[2,3-c]diazanaphthalenes by photocyclization of acylaminopyridines
AU Kanaoka, Yuichi; Sannohe, Kunio; Hatanaka, Yasumaru; Itoh, Kazuhiko; Machida, Minoru; Terashima, Masanao
CS Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan
SO Heterocycles (1977), 6(1), 29-32
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 86:139898
GI



I



II



III

AB Oxidative photocyclization of I (2-, 3- or 4-pyridyl; X = S, NMe) and II (2,3- or 4-pyridyl) gave novel polycyclic systems, e.g., thieno[2,3-c]-, pyrrolo[2,3-c]- and indolo[2,3-c]diazanaphthalenes. E.g., photolysis of I (2-pyridyl, X = S) in the presence of O gave 27% III.

IT **62289-86-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidative photocyclization of)

RN 62289-86-5 CAPLUS

CN 1H-Indole-2-carboxamide, 1-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



=> file uspatall
FILE 'USPATFULL' ENTERED AT 13:58:01 ON 29 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:58:01 ON 29 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 15 1-10 ibib abs hitstr

L5 ANSWER 1 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2005:44368 USPATFULL
TITLE:	Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases
INVENTOR(S):	Erguden, Jens-Kerim, Wulfrath, GERMANY, FEDERAL REPUBLIC OF Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF Schroder, Christian, Bergheim, GERMANY, FEDERAL REPUBLIC OF Stasch, Johannes-Peter, Solingen, GERMANY, FEDERAL REPUBLIC OF Weigand, Stefan, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Wild, Hanno, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Brands, Michael, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005038101	A1	20050217	
APPLICATION INFO.:	US 2004-490821	A1	20040916	(10)
	WO 2002-EP10349		20020916	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-147672	20010927

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
NUMBER OF CLAIMS:	9

EXEMPLARY CLAIM: 1
LINE COUNT: 2640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **509149-88-6P**
(preparation of substituted 2,5-diamidoindoles as endothelin-converting enzyme (ECE) inhibitors for treatment of cardiovascular diseases)
RN 509149-88-6 USPATFULL
CN 1H-Indole-2-carboxamide, N-(5-amino-2-pyridinyl)-5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT **509150-45-2P 509150-46-3P**
(preparation of substituted 2,5-diamidoindoles as endothelin-converting enzyme (ECE) inhibitors for treatment of cardiovascular diseases)
RN 509150-45-2 USPATFULL
CN Carbamic acid, [6-[[[5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-1H-indol-2-yl]carbonyl]amino]-3-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 509150-46-3 USPATFULL
CN 1H-Indole-2-carboxamide, 5-[(3,3-dimethyl-1-oxobutyl)amino]-1-[(2-fluorophenyl)methyl]-N-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2004:300019 USPATFULL		
TITLE:	Utilities of amide compounds		
INVENTOR(S):	Yamamori, Teruo, Hyogo-ken, JAPAN		
	Nagata, Kiyoshi, Osaka-fu, JAPAN		
	Ishizuka, Natsuki, Osaka-fu, JAPAN		
	Sakai, Katsunori, Osaka-fu, JAPAN		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235888	A1	20041125
APPLICATION INFO.:	US 2004-489333	A1	20040421 (10)
	WO 2001-JP7980		20010914
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2017		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments.

Compounds of formula (I): ##STR1##

in which ring A and Ar.sup.1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each of which may be optionally substituted, or the like; R is a hydrogen or the like; Z is oxygen or the like; Y.sup.1 and Y.sup.2 are a hydrogen, a lower alkyl, or the like; n is an integer of 0 to 2; the broken line is the presence or absence of a bond; and the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond; are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **62289-86-5P 340258-78-8P**
(drug candidate; preparation of aryl amides, arylpropenamides, and arylpentadienamides as promoters of apolipoprotein AI expression for the treatment of dyslipidemia and arteriosclerotic diseases)

RN 62289-86-5 USPATFULL

CN 1H-Indole-2-carboxamide, 1-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 340258-78-8 USPATFULL
CN 1H-Indole-2-carboxamide, N-2-pyridinyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2004:292827 USPATFULL
TITLE:	Anti-diabetic agents
INVENTOR(S):	Bussolotti, Donald L., Ledyard, CT, UNITED STATES Gammill, Ronald B., Schoolcraft, MI, UNITED STATES
PATENT ASSIGNEE(S):	Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229916	A1	20041118
APPLICATION INFO.:	US 2004-825279	A1	20040415 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-463691P	20030417 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
LINE COUNT:	1271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula (I) ##STR1##

the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs; wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **781614-93-5P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid ethyl ester
781615-11-0P, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid sodium salt
(drug candidate and intermediate; preparation of N-pyridinyl bicyclic heterocyclic carboxamides as antidiabetics and inhibitors of glycogen phosphorylase)

RN 781614-93-5 USPATFULL
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl-, ethyl ester (9CI) (CA INDEX

NAME)



RN 781615-11-0 USPATFULL
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT **781614-91-3P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-methylpropionic acid ethyl ester **781614-95-7P**, 2-[6-[(5-Chloro-1H-indole-2-carbonyl)amino]-5-ethoxypyridin-3-yl]-2-hydroxypropionic acid **781614-96-8P**, 5-Chloro-1H-indole-2-carboxylic acid N-[5-(1,2-dihydroxy-1-methylethyl)-3-ethoxypyridin-2-yl]amide **781614-98-0P**, 5-Chloro-1H-indole-2-carboxylic acid N-[3-ethoxy-5-[1-hydroxy-1-methyl-2-(morpholin-4-yl)-2-oxoethyl]pyridin-2-yl]amide
(drug candidate; preparation of N-pyridinyl bicyclic heterocyclic carboxamides as antidiabetics and inhibitors of glycogen phosphorylase)
RN 781614-91-3 USPATFULL
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α,α-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 781614-95-7 USPATFULL
CN 3-Pyridineacetic acid, 6-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-ethoxy-α-hydroxy-α-methyl- (9CI) (CA INDEX NAME)



RN 781614-96-8 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[5-(1,2-dihydroxy-1-methylethyl)-3-ethoxy-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 781614-98-0 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[3-ethoxy-5-[1-hydroxy-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2004:280928 USPATFULL
TITLE:	Anti-diabetic agents
INVENTOR(S):	Bussolotti, Donald L., Ledyard, CT, UNITED STATES Gammill, Ronald B., Schoolcraft, MI, UNITED STATES
PATENT ASSIGNEE(S):	Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220229	A1	20041104
APPLICATION INFO.:	US 2004-837468	A1	20040430 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466667P	20030430 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1

LINE COUNT: 1803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula (I) ##STR1##

the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs; wherein R', R", R'", X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **783370-03-6P**
(preparation of indolecarboxamide and thieno[2,3-b]pyrrolecarboxamide derivs., useful as antidiabetic agents)
RN 783370-03-6 USPATFULL
CN 1H-Indole-2-carboxamide, N-[6-amino-4-(ethylsulfonyl)-2-pyridinyl]-5-chloro- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:25173 USPATFULL
TITLE: Protection against and treatment of hearing loss
INVENTOR(S): Nicotera, Thomas, Buffalo, NY, UNITED STATES
Henderson, Donald, Williamsville, NY, UNITED STATES
Hangauer, David G., JR., Amherst, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004019015	A1	20040129	
APPLICATION INFO.:	US 2002-277220	A1	20021019	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-336191P	20011022	(60)
	US 2002-410726P	20020913	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael L. Goldman, Esq., NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603-1051
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 3583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **518060-39-4P**
(preparation of indolecarboxamides as protein kinase and phosphatase inhibitors)
RN 518060-39-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-fluoro-N-2-pyridinyl- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:300887 USPATFULL
TITLE: Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity
INVENTOR(S): Dyatkina, Natalia B., Mountain View, CA, UNITED STATES
Shi, Dong-Fang, Fremont, CA, UNITED STATES
Roberts, Christopher Don, Belmont, CA, UNITED STATES
Velligan, Mark Douglas, Montara, CA, UNITED STATES
Reinhard Liehr, Sebastian Johannes, East Palo Alto, CA, UNITED STATES
Botyanszki, Janos, Fremont, CA, UNITED STATES
Zhang, Wentao, Foster City, CA, UNITED STATES
Khorlin, Alexander, Mountain View, CA, UNITED STATES
Nelson, Peter Harold, Los Altos, CA, UNITED STATES
Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003212113	A1	20031113	
APPLICATION INFO.:	US 2002-328710	A1	20021224	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-343796P	20011226	(60)
	US 2001-343829P	20011226	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 4522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **386252-14-8P**
(drug candidate; preparation of polyamides as antibacterial, antifungal, and/or antitumor agents)

RN 386252-14-8 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1-H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2003:238457 USPATFULL
TITLE:	Protein kinase and phosphatase inhibitors and methods for designing them
INVENTOR(S):	Hangauer, David G., JR., Amherst, NY, UNITED STATES El-Araby, Moustafa E., Plainsboro, NJ, UNITED STATES Milkiewicz, Karen L., Exton, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166615	A1	20030904	
APPLICATION INFO.:	US 2002-277217	A1	20021019	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336191P	20011022 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Michael L. Goldman, Esq., NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603-1051
NUMBER OF CLAIMS:	179
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	17 Drawing Page(s)
LINE COUNT:	5985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis,

immune system activity, Type II diabetes, and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **518060-39-4P**
(preparation of indolecarboxamides as protein kinase and phosphatase inhibitors)
RN 518060-39-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-fluoro-N-2-pyridinyl- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:173901 USPATFULL
TITLE: Novel compounds possessing antibacterial, antifungal or antitumor activity
INVENTOR(S): Zhang, Wentao, Foster City, CA, UNITED STATES
Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA, UNITED STATES
Velligan, Mark Douglas, Montara, CA, UNITED STATES
Dyatkina, Natalia B., Mountain View, CA, UNITED STATES
Botyanszki, Janos, Cupertino, CA, UNITED STATES
Shi, Dong-Fang, San Mateo, CA, UNITED STATES
Roberts, Christopher Don, Belmont, CA, UNITED STATES
Khorlin, Alexander, Mountain View, CA, UNITED STATES
Nelson, Peter Harold, Los Altos, CA, UNITED STATES
Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119749	A1	20030626
APPLICATION INFO.:	US 2002-277666	A1	20021023 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-892327, filed on 26 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 3907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **386252-14-8P**

(preparation of novel compds. possessing antibacterial, antifungal or antitumor activity)

RN 386252-14-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:67203 USPATFULL

TITLE: Novel compounds possessing antibacterial, antifungal or antitumor activity

INVENTOR(S): Zhang, Wentao, Foster City, CA, UNITED STATES
Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA, UNITED STATES
Velligan, Mark Douglas, Montara, CA, UNITED STATES
Dyatkina, Natalia B., Mountain View, CA, UNITED STATES
Botyanszki, Janos, Cupertino, CA, UNITED STATES
Shi, Dong-Fang, San Mateo, CA, UNITED STATES
Roberts, Christopher Don, Belmont, CA, UNITED STATES
Khorlin, Alexander, Mountain View, CA, UNITED STATES
Nelson, Peter Harold, Los Altos, CA, UNITED STATES
Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037856	A1	20020328	
	US 6849713	B2	20050201	
APPLICATION INFO.:	US 2001-892327	A1	20010626	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 3872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **386252-14-8P**
(preparation of novel compds. possessing antibacterial, antifungal or antitumor activity)
RN 386252-14-8 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 10 OF 10 USPAT2 on STN
ACCESSION NUMBER: 2002:67203 USPAT2
TITLE: Compounds possessing antibacterial, antifungal or antitumor activity
INVENTOR(S): Zhang, Wentao, Foster City, CA, United States
Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA, United States
Velligan, Mark Douglas, Montara, CA, United States
Dyatkina, Natalia B., Mountain View, CA, United States
Botyanszki, Janos, Cupertino, CA, United States
Shi, Dong-Fang, San Mateo, CA, United States
Roberts, Christopher Don, Belmont, CA, United States
Khorlin, Alexander, Mountain View, CA, United States
Nelson, Peter Harold, Los Altos, CA, United States
Muchowski, Joseph Martin, Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6849713	B2	20050201
APPLICATION INFO.:	US 2001-892327		20010626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner, LLP, Yang, Julie
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 3787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **386252-14-8P**
(preparation of novel compds. possessing antibacterial, antifungal or antitumor activity)

RN 386252-14-8 USPAT2

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



=>